Similarly, increased CD59 expression has been shown to be associated with reduced survival in CRC patients (23), and with reduced overall survival and progression-free survival in patients with prostate adenocarcinoma and diffuse large B cell lymphoma (24, 25) These studies indicate that complements can be used as biomarkers to assess cancer diagnosis and prognosis and have potential application value in tumor immune regulation. Here, CD59 is linked to colorectal carcinoma.